Abstracts tagged "Pediatric rheumatology"

Abstract Number: 2053 • ACR Convergence 2023
Predictive Factors Associated with Treatment Response in Chronic Nonbacterial Osteomyelitis
Katherine Nowicki¹, Nathan Rogers², Carson Keeter², Nathan Donaldson², Jennifer Soep² and Yongdong (Dan) Zhao³, ¹University of Colorado, Lakewood, CO, ²University of Colorado, Aurora, CO, ³University of Washington, Redmond, WA
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is characterized by sterile inflammatory bone lesions and most commonly affects skeletally immature children. Non-steroidal anti-inflammatory drugs (NSAIDs) are the…
Abstract Number: 2579 • ACR Convergence 2023
Validation of PROMIS in Adult and Pediatric Patients with Idiopathic Inflammatory Myopathies
Emma Austenfeld¹, Sara Sabbagh¹, Melodee Liegl¹, Ke Yan¹, Julie Fuller², Kelly Rouster-Stevens³, Lisa Rider⁴ and Adam Schiffenbauer⁴, ¹Medical College of Wisconsin, Wauwatosa, WI, ²UT Southwestern and Scottish Rite for Children, Dallas, TX, ³Emory University/Children's Healthcare of Atlanta, Norcross, GA, ⁴NIEHS, NIH, Bethesda, MD
Background/Purpose: This study aimed to validate the Patient Reported Outcome Measurement Information System (PROMIS) tools in patients with adult and juvenile idiopathic inflammatory myopathies (IIM/JIIM)…
Abstract Number: 0354 • ACR Convergence 2023
Open-label Phase 3 Study of Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis: Pharmacokinetics, Effectiveness, Safety, and Immunogenicity over 252 Weeks
Nicolino Ruperto¹, Daniel J Lovell², Sarah Ringold³, Xie L. Xu⁴, Jocelyn H. Leu³, Edwin Lam³, Yuhua Wang³, Alberto Martini⁵ and Hermine Brunner⁶, ¹IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy, ²UC Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, OH, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Janssen Research & Development, LLC, San Diego, CA, ⁵Universita degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genova, Italy, ⁶Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH
Background/Purpose: The phase 3, Intravenous Golimumab in Pediatric Participants with Active Polyarticular-Course JIA Despite MTX (GO-VIVA) study demonstrated that golimumab (GLM) 80 mg/m2 at Week…
Abstract Number: 0374 • ACR Convergence 2023
Actionable Adverse Events in a Real-Practice Cohort of Children with Juvenile Idiopathic Arthritis. Results from the CAPRI Registry
Bashayer Alnuaimi¹, Michelle Batthish², Roberta A Berard³, Gilles Boire⁴, Sarah Campillo¹, Amieleena Chhabra⁵, Julie Couture⁶, Paul Dancey⁷, Brian Feldman⁸, Tommy Gerschman⁹, Julie Herrington¹⁰, Kristin Houghton¹¹, Adam Huber¹², Claire LeBlanc¹, Lillian Lim¹³, Jean-Philippe Proulx-Gauthier⁶, Heinrike Schmeling¹⁴, Rosie Scuccimarri¹, Lori Tucker¹⁵, Jaime Guzman¹⁵, Gaëlle Chédeville¹ and For The CAPRI Registry Investigators¹⁶, ¹McGill University Health Center, Montreal, QC, Canada, ²McMaster Children's Hospital, Hamilton, ON, Canada, ³Children's Hospital - London Health Sciences Centre, London, ON, Canada, ⁴Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵British Columbia Hospital, Vancouver, BC, Canada, ⁶CHU de Quebec- Universite Laval, Quebec City, QC, Canada, ⁷Memorial University of Newfoundland, St. John's, NL, Canada, ⁸The Hospital for Sick Children, Toronto, ON, Canada, ⁹British Columbia Children's Hospital, Burnaby, BC, Canada, ¹⁰McMaster University, Hamilton, ON, Canada, ¹¹British Columbia University, Vancouver, BC, Canada, ¹²IWK Health Centre, Halifax, NS, Canada, ¹³University of Alberta, Edmonton, AB, Canada, ¹⁴University of Calgary, Calgary, AB, Canada, ¹⁵British Columbia Children's Hospital, Vancouver, BC, Canada, ¹⁶CAPRI, Montreal, QC, Canada
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory rheumatic disease of childhood and most children require long-term treatment. Adverse events (AE) during…
Abstract Number: 1029 • ACR Convergence 2023
Social Determinants of Health in Children with Rheumatic Disease: A Single Center Cohort
Kristina Ciaglia¹, Elizabeth Sloan¹ and Tracey Wright², ¹UT Southwestern and Scottish Rite for Children, Dallas, TX, ²UT Southwestern, Dallas, TX
Background/Purpose: Rheumatic disease disproportionately impacts certain socioeconomic, racial, and ethnic groups frequently resulting in health care inequities. Social determinants of health (SDOH) are conditions in…
Abstract Number: 1234 • ACR Convergence 2023
Cognitive Performance Score of the Pediatric Automated Neuropsychological Assessment Metrics Software in a Brazilian Cohort and Its Association with Disease Activity
Jaqueline de amorim¹, Simone Kishimoto¹, Paula Fernandes¹, Roberto Marini², Zahi Touma³, Hermine Brunner⁴ and Simone Appenzeller¹, ¹UNICAMP, Campinas, Brazil, ²Revista Brasileira de Reumatologia, Campinas, Brazil, ³University of Toronto, Toronto, ON, Canada, ⁴Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH
Background/Purpose: The PedAnam (Pediatric Automated Neuropsychological Assessment Metrics) is an automatic software to evaluate cognitive performance that has recently been validated into Portugues (Brazil). The…
Abstract Number: 1254 • ACR Convergence 2023
Outcome of Pediatric Lupus in South Asia: Data from Indian SLE Inception Cohort for Research (INSPIRE)
Amita Aggarwal¹, Ranjan Gupta², Liza Rajasekhar³, Ashish J Mathew⁴, Parasar Ghosh⁵, Chengappa Kavadichanda⁶, Vineeta Shobha⁷, Bidyut Das⁸, Manish Rathi⁹, Avinash Jain¹⁰ and Able Lawrence¹, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ²All India Institute of Medical Sciences, New Delhi, India, ³Nizam's Institute of Medical Sciences, Madhapur, India, ⁴Christian Medical College, Vellore, India, ⁵Govt of West Bengal, Kolkata, India, ⁶Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ⁷St. John's National Academy of Health Science, Bangalore, India, ⁸SCB medical college, Cuttack, India, ⁹Postgraduate Institute of Medical education and Research, Chandigarh, India, ¹⁰SMS Medical College, Lucknow, India
Background/Purpose: Juvenile onset SLE (jSLE) has more severe disease and has poorer outcome as compared to adults SLE. Ethnicity affects clinical course and disease outcome…
Abstract Number: 1709 • ACR Convergence 2023
Tape Stripping Expression Signatures Identify Biologically Unique Juvenile Dermatomyositis Patient Subgroup Characterized by Increased Mitochondrial Dysfunction
Jessica Turnier, Celine Berthier, Sarah Vandenbergen, Christine Goudsmit, Madison McClune, Johann E. Gudjonsson, Lam Tsoi and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI
Background/Purpose: Skin inflammation in juvenile dermatomyositis (JDM) can signal disease onset or flare and prevent complete disease remission. The study of cutaneous expression signatures holds…
Abstract Number: 2054 • ACR Convergence 2023
Superiority of Adalimumab in Treating Childhood Chronic Idiopathic Uveitis: Evidence from a Multicentre Experience
Ilaria Maccora¹, Catherine Guly², Lavinia Sanfilippo³, sara Soldovieri⁴, Cinzia De Libero⁵, Athimalaipet V Ramanan⁶ and Gabriele Simonini⁷, ¹PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, ²Ophthalmology Unit, Bristol Eye Hospital, Bristol, United Kingdom, ³Meyer Children's Hospital IRCCC, Florence, Italy, ⁴Rheumatology Unit, ERN ReConnet Center, Meyer Children's Hospital IRCCS, Florence, Italy, ⁵Ophthalmology Unit, Meyer Children's Hospital IRCCS, Florence, Italy, ⁶Bristol Royal Hospital for Children & Translational Health Sciences, University of Bristol, Bristol, United Kingdom, ⁷Rheumatology Unit, ERN ReConnet Center, Meyer Children's Hospital IRCCS, Florence Italy. NeuroFARBA Department, University of Florence, Florence, Italy
Background/Purpose: Childhood Chronic Idiopathic Uveitis (cCIU) is a severe ocular condition that accounts for the 40% of all uveitis in children. Its timely and proper…
Abstract Number: 2589 • ACR Convergence 2023
Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Systemic Lupus Erythematosus
Emily Zhang¹, Sarah Capponi², Rebecca Scobell³, Gabrielle Alonzi¹, Madeline Hlobik¹, Esra Meidan⁴, Mindy Lo⁴, Olha Halyabar⁵, Melissa Hazen¹, Ezra Cohen⁶, Lauren Henderson¹, Siobhan Case⁷, Margaret Chang¹, Ankana Daga¹, Jonathan Hausmann⁸, Ahmad Bakhsh¹, Liyoung Kim¹, Daniel Ibanez¹, Holly Wobma⁴, Fatma Dedeoglu⁴, Robert Sundel¹, Peter Nigrovic¹, Karen Costenbader⁹, Mary Beth Son⁴ and Joyce Chang¹, ¹Boston Children's Hospital, Boston, MA, ²Hospital of the University of Pennsylvania, New Hope, PA, ³Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Division of Immunology, Boston Children's Hospital, Boston, MA, ⁵Children's Hospital/Boston Medical Center, Newton, MA, ⁶Bmc, Needham, MA, ⁷Brigham and Women's Hospital, Boston Children's Hospital, Boston, MA, ⁸Boston Children's Hospital / Massachusetts General Hospital, Cambridge, MA, ⁹Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Chronic glucocorticoid (GC) morbidity is rarely captured as a standardized clinical outcome in pediatric rheumatic conditions. The pediatric glucocorticoid toxicity index (pGTI) (Brogan et…
Abstract Number: 0355 • ACR Convergence 2023
Long Term Safety of Drugs in Systemic Juvenile Idiopathic Arthritis
Ana Isabel Rebollo Gimenez¹, Luca Carlini², Paivi Miettunen³, Ekaterina Alexeeva⁴, Charlotte Myrup⁵, Rebecca Nicolai⁶, Maria Trachana⁷, Valda Stenevicha⁸, Constantin Ailioaie⁹, Elena Tsitsami¹⁰, Alexis-Virgil Cochino¹¹, Chiara Pallotti¹², Silvia Scala¹², Angela Pistorio¹³, Sebastiaan Vastert¹⁴, Joost Swart¹⁵ and Nicolino Ruperto¹⁶, ¹IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy, ²IRCCS Istituto Giannina Gaslini, UOC Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, Genoa, Italy, ³University of Calgary and Alberta Children’s Hospital, Calgary, AB, Canada, ⁴Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, ⁵Pediatric rheumatology unit 4272, Rigshospitalet, Copenhagen, Denmark, ⁶Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁷First Department of pediatrics, Pediatric Immunology and Rheumatology Referral Center, Hippokration General Hospital, Thessaloniki University School of Medicine, Thessaloniki, Greece, ⁸Department of Paediatrics, Riga Stradins University, Children University Hospital, Riga, Latvia, ⁹Pediatric Rheumatology , Alexandru Ioan Cuza University of Iasi, Iasi, Romania, ¹⁰Pediatric Rheumatology Unit, 1st Department of Pediatrics, Children's Hospital "Aghia Sophia", University of Athens, Athens, Greece, ¹¹First Department of Pediatrics, University of Athens Medical School, Aghia Sophia Childrens Hospital, Athens, Greece, ¹²Pediatric and Rheumatology Clinic, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ¹³Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ¹⁴University Medical Center Utrecht, Utrecht, Netherlands, ¹⁵Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Netherlands, ¹⁶IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy
Background/Purpose: Evidence on treatment safety in systemic juvenile idiopathic arthritis (sJIA) is limited. Our objective was to evaluate the safety profile of drugs in the…
Abstract Number: 0379 • ACR Convergence 2023
Clinical Evolution of Patients Diagnosed of Juvenile Idiopathic Arthritis After the Transitional Care Consultation
Alba Maria Torrat Noves¹, Rebeca Perpiñan Perez², Jose Ivorra Cortes¹, Elena Grau Garcia¹, Daniel Ramos Castro¹, Pablo Francisco Muñoz Martínez³, Laura Mas Sanchez⁴, Carmen Riesco Barcena¹, Anderson Victor Huaylla Quispe¹, Samuel Leal Rodriguez¹, Belen Villanueva Mañez¹, Iago Alcantara Alvarez¹, Isabel Martinez Cordellat¹, Luis Gonzalez Puig¹, Rosa Negueroles Albuixech¹, Jose Eloy Oller Rodriguez¹, Elvira Vicens Bernabeu¹, Ernesto Tovar Sugrañes¹, Marta De la Rubia Navarro⁴, Hikmat Charia¹, Ines Canovas Olmos¹, Carmen Najera Herranz¹ and Jose Andres Roman Ivorra⁵, ¹Rheumatology Department. HUP La Fe, Valencia, Spain, ²Universidad Catolica de Valencia San Vicente Martir, Valencia, Spain, ³Rheumatology Department. HUP La Fe, Sagunto, Spain, ⁴Rheumatology Department. HUP La Fe, Valéncia, Spain, ⁵Hospital Universitari i Politècnic la Fe, Valencia, Spain
Background/Purpose: Juvenile idiopathic arthritis (JIA) encompasses a group of chronic arthritis that begin in childhood. According to the International League of Associations for Rheumatology (ILAR)…
Abstract Number: 1085 • ACR Convergence 2023
Utilizing a Maintenance of Certification (MOC) Part 4 Quality Improvement Project to Improve Data Completeness in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Hemalatha Srinivasalu¹, anne dennos², alan Russell³, Mary Beth Son⁴ and Mara Becker², ¹Children's National Hospital, Washington, DC, ²Duke University, Durham, NC, ³Duke Clinical Research Institute, Duke, NC, ⁴Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Minimizing missing data in research registries is a universal challenge. Enrolling patients into a research registry with poor data quality is wasteful and potentially…
Abstract Number: 1235 • ACR Convergence 2023
Apparent Diffusion Coefficient (ADC) from Diffusion Weighted Imaging (DWI) as an Objective Tool to Differentiate Normal Maturational Subchondral Signal from Inflammation at the Sacroiliac Joint in Youth
Michael L. Francavilla¹, Dmitry Khrichenko², Timothy G. Brandon², Nancy A. Chauvin³, Rui Xiao⁴ and Pamela F. Weiss⁵, ¹University of South Alabama College of Medicine, Mobile, AL, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³The Cleveland Clinic, Hummelstown, PA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: There is a critical need for tools to distinguish between maturational changes mimicking subchondral edema from pathologic inflammation within the SI joints on MRI.…
Abstract Number: 1255 • ACR Convergence 2023
Clinical Characteristics and Disease Outcomes of anti-NXP2 Positive Juvenile Dermatomyositis: A Single Center Cohort
Sarah Molina¹, Dawn Gist², Marietta De Guzman³, Eyal Muscal⁴, Jamie Lai² and Maria Pereira³, ¹Baylor College of Medicine - Pediatrics Residency Program, Houston, TX, ²Baylor College of Medicine / Texas Children's Hospital, Houston, TX, ³Baylor College of Medicine, Houston, TX, ⁴Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, TX
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare idiopathic inflammatory myopathy with clinically heterogeneous presentations that can be categorized by myositis-specific antibodies (MSAs). NXP2 is among…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].